Strategic backing Tubulis is now part of Gilead Sciences, indicating strong strategic alignment, potential access to broader distribution channels, and enhanced credibility when engaging with partners, which can shorten sales cycles for collaboration or platform licensing opportunities.

Clinical expansion With ongoing development of TUB-030 and a focus on solid tumor indications, there are multiple near-term clinical milestones and potential partnership or co-development opportunities around ADC technology, biomarker strategies, and trial support services.

ADC platform focus Tubulis emphasizes an antibody-drug conjugate platform targeting solid tumors and P5 technology, offering sales angles around novel payloads, linker technologies, and translational capabilities for CROs, contract services, or collaboration on ADC programs.

Scientific leadership Award recognition (Friedrich Stolz Award 2026) and collaborations with academic partners signal strong R&D credibility, creating a compelling case for engaging researchers, grant-influenced collaborations, and sponsored research or technology licensing discussions.

Funding momentum Recent Series C funding and a sizable funding pool alongside revenue growth position Tubulis as a scalable partner for供应 of research tools, manufacturing process development, clinical trial support, and pilot manufacturing services to accelerate their oncology programs.